Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most promising therapeutic options. As liver is the most frequent site of metastatic disease, our project proposes to compare administration of radiolabeled SSA by arterial intrahepatic infusion (experimental approach) vs intravenous administration (conventional). Evaluation will be made by (i) comparing 68Ga-DOTA-peptides uptake after intra-hepatic versus intravenous route (imaging), (ii) by evaluating the safety of an additional intra-hepatic administration of therapeutic radiolabeled SSA (therapy).
Sponsor:
University Hospital, Bordeaux
Phase:
Phase 2
Contacts:
Ghoufrane TLILI, Drghoufrane.tlili@chu-bordeaux.fr
05 57 65 64 08
Macary Guillaumeguillaume.macary@chu-bordeaux.fr
05 57 62 32 52
Government Study Link:
NCT04837885 - Click here to see study onClinicalTrials.gov
Help us improve your experience